KZIA 0.55 Kazia Therapeutics Limited
| Range: | 0.19-1.58 | Vol Avg: | 1449384 | Last Div: | 0 | Changes: | -0.02 |
| Beta: | 2.1 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Jan 06 1999 | Empoloyees: | 9 | ||
| CUSIP: | 48669G105 | CIK: | 0001075880 | ISIN: | US48669G1058 | Country: | AU |
| CEO: | Dr. John Edwin Friend II, M.D. | Website: | https://www.kaziatherapeutics.com | ||||
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow